Takeda Pharmaceutical TKPHF
NYSE TKPHF
$34.00 +0.00 (+0.00%)
At close: Aug 19, 2026 · 4:00 PM EDT

Takeda Pharmaceutical Co Ltd (TKPHF) EBIT (2017 - 2026)

Takeda Pharmaceutical (TKPHF) posted quarterly EBIT of $1.3 billion for Q2 2026, down 0.93% year-over-year from $1.3 billion in Q2 2025, and down 1.6% quarter-over-quarter from $1.3 billion in Q1 2026.

Takeda Pharmaceutical Co Ltd (TKPHF) EBIT (2017 - 2026) Analysis & Trends

Takeda Pharmaceutical's EBIT history runs 10 years deep, the most recent figure standing at $1.3 billion for Q2 2026.

  • In Q2 2026, EBIT fell 0.93% year-over-year to $1.3 billion; the TTM figure through Jun 2026 stood at $2.7 billion (down 43.44% YoY), while the FY2026 annual figure was $41.3 million, down 98.16% from the prior year.
  • EBIT for Q2 2026 stood at $1.3 billion, down from $1.3 billion in the prior quarter.
  • The five-year high for EBIT was $2.9 billion in Q3 2025, with the low at -$2.7 billion in Q4 2025.
  • The 5-year median for EBIT is $1.2 billion (2025), against an average of $1.1 billion.
  • The sharpest annual moves came in 2023 and 2025: EBIT jumped 268.02% in 2023, then slumped 448.93% in 2025.
  • Takeda Pharmaceutical's EBIT stood at $1.0 billion in 2022, then slumped by 42.39% to $599.4 million in 2023, then plunged by 182.19% to -$492.7 million in 2024, then plunged by 448.93% to -$2.7 billion in 2025, then soared by 146.73% to $1.3 billion in 2026.
  • Business Quant data shows TKPHF's EBIT at $1.3 billion in Q2 2026, $1.3 billion in Q1 2026, and -$2.7 billion in Q4 2025.

Peer Comparison

Historic Data

Download Data
DateValue
Jun 30, 2026 1.26 Bn
Mar 31, 2026 1.28 Bn
Dec 31, 2025 -2.70 Bn
Sep 30, 2025 2.87 Bn
Jun 30, 2025 1.28 Bn
Mar 31, 2025 1.21 Bn
Dec 31, 2024 -492.68 Mn
Sep 30, 2024 2.80 Bn
Jun 30, 2024 1.07 Bn
Mar 31, 2024 1.14 Bn
Dec 31, 2023 599.40 Mn
Sep 30, 2023 2.78 Bn
Jun 30, 2023 1.23 Bn
Mar 31, 2023 1.27 Bn
Dec 31, 2022 1.04 Bn
Sep 30, 2022 756.19 Mn
Jun 30, 2022 1.16 Bn
Mar 31, 2022 2.14 Bn
Dec 31, 2021 1.02 Bn
Sep 30, 2021 885.03 Mn